NHWA(SZ:002262) Zheng Quan Zhi Xing·2025-04-19 22:25Financial Performance - The company reported a total revenue of 1.511 billion yuan for Q1 2025, an increase of 11.29% year-on-year [1] - The net profit attributable to shareholders reached 301 million yuan, reflecting a year-on-year growth of 13.35% [1] - The gross profit margin improved to 74.69%, up by 5.53% compared to the previous year [1] - The net profit margin also increased to 19.9%, a rise of 2.08% year-on-year [1] - The company's operating cash flow per share was 0.31 yuan, marking a significant increase of 35.53% year-on-year [1] Accounts Receivable and Liabilities - Accounts receivable rose significantly, with a year-on-year increase of 50.86%, reaching 1.686 billion yuan [1] - The company reduced its interest-bearing liabilities by 62.21%, bringing them down to 31.721 million yuan [1] Market Position and Analyst Insights - The company's return on invested capital (ROIC) was reported at 16.19%, indicating strong capital returns [3] - Analysts expect the company's revenue for 2025 to be around 1.32 billion yuan, with an average earnings per share forecast of 1.3 yuan [3] - The company has a notable presence among institutional investors, with a prominent fund manager recently increasing their stake [3] Fund Holdings - The largest fund holding the company’s shares is the Huatai-PineBridge Innovation Medicine Mixed Fund, which has a scale of 4.675 billion yuan [4] - The fund manager of this fund has a strong track record, ranking second in the 2024 public fund manager list [4] Strategic Plans - The company plans to accelerate the launch of new drugs and enhance the promotion of existing non-collection products while managing costs effectively [5]